Genomma Lab Intl Sab Ord (GNMLF) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for joining Genoma Lab's second quarter 2024 earnings conference call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. As a reminder, this meeting is being recorded and will be available for replay from the Investor Relations section of Genoma's website following the call. I'll now turn the call over to Christian Ibanez, Genoma's Head of Investor Relations. Please, go ahead. Thank you and welcome, everyone. On today's call are Marcos Barbieri, Chief Executive Officer, and Antonio Zamora, Chief Financial Officer. Before we get started, I'd like to remind you that the remarks today will include forward-looking statements such as the company's financial guidance and expectations, including long-term objectives and forecasts, as well as expectations regarding Genoma's business, assets, products, strategies, demand, and markets. These statements are subject to risks and uncertainties that could cause actual results to differ materially. They are also based on assumptions as of today, and the company undertakes no obligation to update them as a result of new information or future events. Let me now turn the call over to Marco. Thank you, Chris. Good morning, everyone. I'm excited to announce Strong Quarter 2 2024 results. The highlight of the quarter is the profitability results with improvements across the P&L, starting with a gross margin that reached a very healthy level of 64%, that is 7.1 points of improvement over the past one and a half years. EBDA margin grew to 22.9%, a 186 basis points increase versus last year. Net income grew 50.1% to 631 million pesos. And EPS grew by 53.1% to 0.63 pesos. These results are driven by efficiencies in our San Cayetano manufact...